Studies of CDK4/6 inhibitors combined with immune checkpoint inhibitors and other antitumor agents are assessing whether preclinical signs of synergy translate into therapeutic efficacy in patients with NSCLC [14,15,16]. Here, CDK4 is linked to non-small cell lung carcinoma.